Figure 1.

Adult and pediatric-mBL cases are indistinguishable by the Burkitt classifier but have distinct CNAs. (A) Heat map showing expression of genes in the Dave et al⁶ and Hummel et al⁷ Burkitt classifiers for a BL and DLBCL training cohort and a validation cohort consisting of adult-BL, pediatric-BL, nonmolecularly classified Burkitt, and t(8;14)-positive DLBCL tumors. MYC and BCL2 translocation status of the 61 cases in the study are noted, and cases in which the translocation status comes solely from NGS data are marked (·). (B) Comparison of the mBL probability score predicted by the Dave et al⁶ and Hummel et al⁷ BL classifiers. Three cases classified as Burkitt by the Dave classifier would be classified as intermediate by the Hummel classifier. (C) Kaplan-Meier curves comparing overall survival of adult and pediatric molecularly classified Burkitt cases. The adult-BL series shows dismal clinical outcome, which may be attributed to suboptimal treatment, diagnostic challenges (before the GEP era), double-hit cases with mBL features, and advanced age (median, 55 years).